netFormulary

North East and North Cumbria
ICS Formulary

8 Malignant disease and immunosuppression

08-03-04-02 Gonadorelin analogues

Clinicians are encouraged to prescribe the least expensive product that is clinically appropriate.

Goserelin

First Choice

Leuprorelin Acetate

First Choice

Triptorelin

First Choice

Approved formulations include triptorelin 3mg, 11.25mg and 22.5mg IM injection for the treatment of prostate cancer

Please note for the treatment of precocious puberty please refer to Chapter 6 Drugs affecting gonadotrophins

Degarelix

First Choice

Approved formulations include 80mg and 120mg vials (with diluent).
Approved for the first line treatment of advanced hormone dependant prostate cancer with a PSA > 20ng/l at presentation
- -approved as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases in line with NICE.

Buserelin

Formulary

Approved formulations include:
- 5mg in 5ml injection;
- 150 microgram metered dose nasal spray.

Links